Literature DB >> 7855102

[Osteosarcoma--apoptosis and proliferation. Study of bcl-2 expression].

M Pösl1, M Amling, M Werner, I Bäsler, M Salzer-Kuntschik, K Winkler, G Delling.   

Abstract

The relationship between the growth of tumors and the expression of the protooncogene Bcl-2 could be shown in epithelial tumors. A bcl-2 expression leads to a prolonged cell survival due to an inhibition of apoptosis. The potential meaning of bcl-2 expression in mesenchymal tumors remains still unknown. The fact, that the heterogenous group of osteosarcoma is not sufficiently characterized at present, suggested to investigate the bcl-2 expression in osteosarcoma. Thus, immunohistochemistry was used to analyze 47 specimens of different osteosarcomas of 36 patients. Sixteen cases (46%) showed a strong expression of bcl-2 and 13 cases (35%) were moderately positive for bcl-2. Seven cases (19%) were negative for bcl-2. The heterogenous, negative up to strong expression of bcl-2 yield clues, that the Bcl-2 controlled regulation of programmed cell death could be an important factor of cellular kinetics. Additionally the cellular proliferation rate was determined with the monoclonal antibody MIB 1, directed against the Ki-67 epitope. The data of bcl-2 expression and cellular proliferation rate lead to a classification correlating with the histological classification. To verify the importance of apoptosis in the genesis of mesenchymal tumors and whether Bcl-2 may play an important role as a predictive factor for the prognosis of osteosarcoma, further investigations will be needed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7855102     DOI: 10.1007/s002920050063

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  7 in total

1.  Lack of association between bcl-2 expression and prognosis of osteosarcoma: a meta-analysis.

Authors:  Tao Fu; Chengyan Xia; Zonghuan Li; Hua Wu
Journal:  Int J Clin Exp Med       Date:  2015-06-15

2.  Livin and Bcl-2 expression in high-grade osteosarcoma.

Authors:  T Nedelcu; B Kubista; A Koller; I Sulzbacher; I Mosberger; F Arrich; K Trieb; R Kotz; C D Toma
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-14       Impact factor: 4.553

3.  Immunohistochemical Estimates of Angiogenesis, Proliferative Activity, p53 Expression, and Multiple Drug Resistance Have No Prognostic Impact in Osteosarcoma: A Comparative Clinicopathological Investigation.

Authors:  Flemming Brandt Sorensen; Kenneth Jensen; Michael Vaeth; Henrik Hager; Anette Mariane Daa Funder; Akmal Safwat; Johnny Keller; Mariann Christensen
Journal:  Sarcoma       Date:  2009-02-25

4.  Bcl-2 correlates with localization but not outcome in human osteosarcoma.

Authors:  Klemens Trieb; Irene Sulzbacher; Bernd Kubista
Journal:  Oncol Lett       Date:  2013-06-13       Impact factor: 2.967

5.  MicroRNA-29b-1 impairs in vitro cell proliferation, self‑renewal and chemoresistance of human osteosarcoma 3AB-OS cancer stem cells.

Authors:  Riccardo Di Fiore; Rosa Drago-Ferrante; Francesca Pentimalli; Domenico Di Marzo; Iris Maria Forte; Antonella D'Anneo; Daniela Carlisi; Anna De Blasio; Michela Giuliano; Giovanni Tesoriere; Antonio Giordano; Renza Vento
Journal:  Int J Oncol       Date:  2014-08-22       Impact factor: 5.650

Review 6.  Understanding the Biology of Bone Sarcoma from Early Initiating Events through Late Events in Metastasis and Disease Progression.

Authors:  Limin Zhu; Madonna M McManus; Dennis P M Hughes
Journal:  Front Oncol       Date:  2013-09-17       Impact factor: 6.244

7.  Decreased WWOX expression promotes angiogenesis in osteosarcoma.

Authors:  Jia Wen; Zongchao Xu; Jiazhen Li; Yingqiang Zhang; Wenzhe Fan; Yu Wang; Mingjian Lu; Jiaping Li
Journal:  Oncotarget       Date:  2017-04-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.